ImmunisBio, NK Cell Culture Medium Shows Skin Regeneration and Wrinkle Formation Inhibition Effects
[Asia Economy Reporter Hyungsoo Park] Immunis Bio announced on the 25th that it has confirmed the skin wound healing and wrinkle formation inhibition effects of the NK cell culture medium it produces, and published a paper in the international journal Journal of Cosmeticsm, Dermatological Science and Applications.
They confirmed the potential of NKEL (NK-enriched lymphocyte) culture medium, obtained through Immunis Bio's unique NK cell culturing method and culture medium production technology, as a cosmeceutical ingredient.
Kang Jeonghwa, CEO and corresponding author of the paper, stated, "The NKEL culture medium developed by our company contains various anti-inflammatory cytokines and growth factors," adding, "Through this, it can activate cell migration and reduce the expression of matrix metalloproteinases (MMPs), which are protein-degrading enzymes, thereby improving the rate of skin cell regeneration."
She continued, "We confirmed that the cytokines inside the culture medium reduce collagen-degrading components, inhibiting wrinkle formation," and added, "Since skin cells grow and their mobility increases, it shows an anti-aging effect by reducing wrinkles."
Based on this research paper, Immunis Bio plans to further develop dermacosmetic products containing the cell culture medium that are equivalent to functional cosmetics and pharmaceuticals. They will expand product lines for skin regeneration, atopy relief, and anti-inflammation.
Hot Picks Today
"Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- Bull Market End Signal? Securities Firm Warns: "Sell SK hynix 'At This Moment'"
- "Greater Impact on Women Than Men"... The 'Diet Trap' That Causes Sleepless Nights and Suffering
- "Even With a 90 Million Won Salary and Bonuses, It Doesn’t Feel Like Much"... A Latecomer Rookie Who Beat 70 to 1 Odds [Scientists Are Disappearing] ③
Immunis Bio is researching NK and Treg-related immune cell therapies for cancer and autoimmune disease treatment, and is expanding its business area by developing automated devices for cell therapy production. They are preparing for a KOSDAQ market technology special listing underwritten by Kiwoom Securities in the second half of this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.